Golembiewska E, Qureshi AR, Dai L, et al. - Given that vascular calcification (VC) is an independent predictor of cardiovascular disease (CVD) present in 30–70% of individuals with chronic kidney disease (CKD), researchers intended to determine if there is a connection between copeptin and VC in CKD stage 5. In 149 clinically stable CKD stage 5 patients (CKD5), including 53 non-dialyzed (CKD5-ND) and 96 dialysis patients treated by peritoneal dialysis (PD) (n = 43) or hemodialysis (HD) (n = 53), copeptin was investigated in conjunction with living donor kidney transplantation. Findings suggested an independent association of high circulating levels of copeptin in CKD5 patients with the degree of medial calcification ascertained by histology of arterial biopsies. Consequently, plasma copeptin can serve as a marker of the uremic calcification process.